Diagnostic Impact of Liver Biopsy Among Antinuclear Antibody Positive Individuals With Mild Liver Enzyme Elevation.
Liver biopsy provides limited additional diagnostic value in ANA-positive patients with mild liver enzyme elevation, particularly when alanine aminotransferase is below 101 U/L.
Where it sits
this study against the rest of the goserelin corpusSummary and findings
This study evaluated the diagnostic yield of liver biopsy in antinuclear antibody positive individuals with mild liver enzyme elevation, specifically those with alanine aminotransferase below 101 U/L. A total of 313 adults were analyzed, with findings indicating limited additional diagnostic value for liver biopsy in this population. Only 9% of patients with positive antinuclear antibodies and alanine aminotransferase < 101 U/L showed autoimmune hepatitis compatible histology.
Abstract
<h4>Background and aims</h4>Abnormal liver enzyme elevations with positive antinuclear antibodies (ANA) frequently prompt investigation for autoimmune hepatitis after common causes such as viral hepatitis or drug-induced liver injury have been excluded. Current guidelines recommend liver biopsy for suspected autoimmune hepatitis, but its utility in patients with only mild transaminase elevation remains uncertain. This study evaluated the diagnostic yield of liver biopsy in such patients, particularly when alanine aminotransferase is below 101 U/L.<h4>Methods</h4>We retrospectively analysed 313 adults who underwent percutaneous liver biopsy at the University Hospital Heidelberg between 2019 and 2024 for unexplained liver enzyme elevation including suspected autoimmune hepatitis. Clinical data were extracted, and histology was classified according to the 2022 International Autoimmune Hepatitis Pathology Group consensus recommendations. Patients with malignancy, post-transplant biopsy, or incomplete data were excluded.<h4>Results</h4>The median age was 49 years; 55.3% were female. Median alanine aminotransferase and aspartate aminotransferase were 161 U/L and 106 U/L, respectively. Antinuclear antibodies were positive in 61.3% of cases. 22.4% of antinuclear antibody positive and 15.7% of antinuclear antibody negative patients had autoimmune hepatitis compatible histology. Among patients with positive antinuclear antibodies and alanine aminotransferase < 101 U/L, only 9% showed autoimmune hepatitis compatible histology and 3.8% (three patients) required long-term immunosuppression. Two of these three patients had compensated liver cirrhosis.<h4>Conclusions</h4>Liver biopsy provides limited additional diagnostic value in ANA-positive, non-cirrhotic patients with alanine aminotransferase < 101 U/L and no alternative suspected aetiology. In such cases, the procedure can be safely deferred, reserving biopsy for higher enzyme elevations or unclear differential diagnoses.
Background
This paper addresses the diagnostic utility of liver biopsy in patients with mild liver enzyme elevations and positive antinuclear antibodies, a scenario that often raises concern for autoimmune hepatitis. Previous guidelines recommend biopsy for suspected autoimmune hepatitis, but its necessity in cases of mild transaminase elevation is unclear. Understanding the diagnostic yield in this specific patient group is important for optimizing clinical decision-making and resource utilization.
Methods
The study employed a retrospective design analyzing 313 adults who underwent percutaneous liver biopsy for unexplained liver enzyme elevation at the University Hospital Heidelberg from 2019 to 2024. Patients with malignancy, post-transplant biopsy, or incomplete data were excluded. The primary outcome measure was the histological classification of liver biopsy results according to the 2022 International Autoimmune Hepatitis Pathology Group consensus recommendations.
Results
The primary finding indicated that among patients with positive antinuclear antibodies and alanine aminotransferase < 101 U/L, only 9% showed autoimmune hepatitis compatible histology. The study also reported that 22.4% of antinuclear antibody positive patients had autoimmune hepatitis compatible histology overall. Additionally, 3.8% of patients required long-term immunosuppression, with two of these patients having compensated liver cirrhosis.
Interpretation
The findings suggest that liver biopsy may have limited diagnostic value in patients with mild enzyme elevations and positive antinuclear antibodies, as only a small percentage showed autoimmune hepatitis compatible histology. This contrasts with existing guidelines that recommend biopsy in suspected cases, indicating a need for reevaluation of such practices. Confounding factors include the study's retrospective nature and the specific population studied, which may limit the generalizability of the results to broader clinical settings.
Key findings
- Median age was 49 years; 55.3% were female.
- Median alanine aminotransferase was 161 U/L and aspartate aminotransferase was 106 U/L.
- Antinuclear antibodies were positive in 61.3% of cases.
- 22.4% of antinuclear antibody positive patients had autoimmune hepatitis compatible histology.
- Among patients with positive antinuclear antibodies and alanine aminotransferase < 101 U/L, only 9% showed autoimmune hepatitis compatible histology.
- 3.8% (three patients) required long-term immunosuppression.
Limitations
- Retrospective study design.
- Single institution analysis may limit generalizability.
- Selection bias possible due to exclusion criteria.
- Short follow-up duration for assessing long-term outcomes.